David V. Erbe - Concepedia

Author

David V. Erbe

Alnylam Pharmaceuticals (United States)

Also Known As

David Erbe, David V Erbe, David V. Erbe, David V. Erbe ., David V. Erbe, David V. Erbe

Publications

Citations

H-Index

Concepts

All Affiliations

Alnylam Pharmaceuticals (United States)Pfizer (United States)Women's Health Research Institute University College London University of Pennsylvania

About

David V. Erbe is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, natural sciences, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	1.4K
2	Natural Sciences	8	8	764
3	Biochemistry	8	8	694
4	Engineering	1	1	111
5	Health Sciences	1	1	41

David V. Erbe

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses Carin C. Stamper, Yan Zhang, James F. Tobin, Nature Crystal StructureB7-1/ctla-4 ComplexHuman Immune ResponsesImmune RegulationImmunology	2001	477
An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria Abigail Liebow, Xingsheng Li, Timothy Racie, Journal of the American Society of Nephrology Translational MedicineBiochemistryPrimary HyperoxaluriaGlycolate OxidaseLiver Physiology	2016	198
Structure-Based Optimization of Protein Tyrosine Phosphatase 1B Inhibitors: From the Active Site to the Second Phosphotyrosine Binding Site Douglas Wilson, Zhao‐Kui Wan, Weixin Xu, Journal of Medicinal Chemistry Proteinlipid InteractionDrug TargetMolecular BiologyStructure-based OptimizationEnzyme Active Site	2007	156
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent Dean R. Artis, Jack J. Lin, Chao Zhang, Proceedings of the National Academy of Sciences Metabolic SyndromeMedicinal ChemistryBiochemistryG Protein-coupled ReceptorMedicine	2008	146
Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists David V. Erbe, Katherine Gartrell, Yanling Zhang, Vascular Pharmacology Molecular PharmacologySignal TransductionMolecular PhysiologyG Protein-coupled ReceptorMedicine	2006	136
Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface Michael M. Schmidt, Sharon A. Townson, Amy Andreucci, Structure Crystal StructureEngineeringProtein AssemblyCompetitive MimicryNatural Sciences	2013	111
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis Simina Ticau, Gautham Sridharan, Shira Tsour, Neurology	2020	95
Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms David V. Erbe, Suyue Wang, Yanling Zhang, Molecular Pharmacology	2004	82
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1 Yaacov Frishberg, Georges Deschênes, Jaap W. Groothoff, Clinical Journal of the American Society of Nephrology	2021	78
A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia Lacramioara Ivanciu, Raffaella Toso, Paris Margaritis, Nature Biotechnology HematologyImmunologyPathologyHemostasisCoagulopathy	2011	71

Page 1